Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: Exploratory analyses

Clinical Oncology

Volumn 25, Issue 4, 2013, Pages 217-226

  Lipton, A ^a   Cook, R ^b   Brown, J ^c,d   Body, J J ^e   Smith, M ^f   Coleman, R ^d  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Bone marker; Bone metastases; Bone resorption; Skeletal related events; Survival; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; COVARIANCE; DEATH; EXPLORATORY RESEARCH; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MORBIDITY; NEPHROTOXICITY; OSTEOLYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOLYSIS; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875368229     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.11.004     Document Type: Article

References (23)

1. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12(Suppl.):6243s-6249s.
2. Suva L.J., Griffin R.J., Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 2009, 16:703-713.
3. Costa L., Lipton A., Coleman R.E. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 2006, 3:143-153.
4. Delea T., McKiernan J., Brandman J., et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006, 4:341-347.
5. Delea T.E., McKiernan J., Brandman J., et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006, 1:571-576.
6. Lage M.J., Barber B.L., Harrison D.J., et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008, 14:317-322.
7. Saad F., Lipton A., Cook R., et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
8. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
9. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
10. Lipton A., Costa L., Ali S.M., et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001, 27:181-185.
11. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
12. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7:377-387.
13. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
14. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
15. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
16. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
17. Fukumitsu N., Uchiyama M., Mori Y., et al. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients. Metabolism 2002, 51:814-818.
18. Chesnut C.H., Bell N.H., Clark G.S., et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997, 102:29-37.
19. Conte P., Rosen L.S., Gordon D., et al. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications. Ann Oncol 2004, 15(Suppl. 3):iii124.
20. Coleman R., Brown J., Terpos E., et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008, 34:629-639.
21. Lipton A., Cook R.J., Major P., et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
22. Eck S.M., Hoopes P.J., Petrella B.L., et al. Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 2009, 116:79-90.
23. Garnero P., Ferreras M., Karsdal M.A., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18:859-867.